You just read:

Ibrutinib (IMBRUVICA®) Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for the Development of a Treatment for Chronic Graft-Versus-Host Disease (cGVHD)

News provided by

Janssen Pharmaceutical Companies

29 Jun, 2016, 07:35 ET